Open Orphan PLC Notice of AGM (2565R)
26 Giugno 2020 - 2:05PM
UK Regulatory
TIDMORPH
RNS Number : 2565R
Open Orphan PLC
26 June 2020
26 June 2020
Open Orphan plc
("Open Orphan" or the "Group")
Notice of AGM
Open Orphan plc (ORPH), a rapidly growing specialist CRO
pharmaceutical services company which is the world leader in the
testing of vaccines and antivirals using human challenge study
models announces that its Annual Report and Accounts for the year
ended 31 December 2019 and the notice of the 2020 Annual General
Meeting ("AGM"), will be posted to shareholders later today , and
will shortly be available on the Company's website,
https://www.openorphan.com/ .
The Company's AGM will be held at the offices of Arden Partners
PLC, 125 Old Broad St, London EC2N 1AR on 22 July 2020 at 12
noon.
IMPORTANT NOTICE REGARDING COVID-19
In light of the UK Government's response to the COVID-19
outbreak, which includes banning most non-essential travel and
gatherings of more than two people, the Company and the Executive
Chairman have determined that the Resolutions to be proposed at the
AGM shall be voted on through a poll rather than on a show of
hands. The Company believes that this is the best and fairest way
to ensure that the votes of all shareholders can be taken into
account, whilst also preventing the Company and shareholders
breaching applicable regulations. Accordingly, the Company
encourages all shareholders to either submit their Form of Proxy or
use the CREST Proxy Voting Service, rather than attend the meeting
in person. In accordance with the Company's articles of
association, whilst completion and return of the Form of Proxy or
using the CREST Proxy Voting Service would not preclude
shareholders from attending, speaking and voting in person at the
AGM should they so wish, shareholders are reminded that to do so
would potentially be in breach of UK Government regulations in
relation to the containment and control of COVID-19 and accordingly
shareholders are strongly encouraged to either submit their Form of
Proxy or use the CREST Proxy Voting Service, rather than attend the
AGM in person.
For further information please contact
+353 (0)1 644
Open Orphan plc 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser +44 (0)20 7614
and Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
+44 (0) 20 7220
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint +353 (0)1 679
Broker) 6363
Anthony Farrell
+44 (0)20 3757
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical
services group which is a world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.
Conducted from Europe's only 24-bedroom quarantine clinic with
onsite virology providing individually isolated rooms and connected
to our specialist laboratory facility. Which offers highly
specialised virology and immunology laboratory services to support
pre-clinical and clinical respiratory drug, antiviral, and vaccine
discovery and development. Reliable laboratory analysis underpinned
by scientific expertise is essential when processing and analysing
clinical samples. Robust quality processes support our team of
scientists in the delivery of submission ready data.
The Group has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. In June 2020 hVIVO COVID Clear Test was
launched, the most accurate antibody test available to UK
employers, helping them to get their people back to work.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences , and is developing an
early stage orphan drug genomics data platform business. This
platform captures valuable genetic data from patient populations
with specific diseases with designated orphan drug status and
incorporating AI tools. In June 2019, Open Orphan acquired
AIM-listed Venn Life Sciences Holdings plc in a reverse take-over
and in January 2020 it completed the merger with hVIVO plc. Venn,
as an integrated drug development consultancy, offers CMC
(chemistry, manufacturing and controls), preclinical, Phase I &
II clinical trials design and execution. The merger with hVIVO
created a European full pharma services group broadening the
Group's customer base and with complementary specialist CRO
services, widened the range of the Group's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAPPUWUQUPUGPQ
(END) Dow Jones Newswires
June 26, 2020 08:05 ET (12:05 GMT)
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Apr 2023 a Apr 2024